PMID- 12117585
OWN - NLM
STAT- MEDLINE
DCOM- 20030205
LR  - 20190712
IS  - 0091-3057 (Print)
IS  - 0091-3057 (Linking)
VI  - 73
IP  - 2
DP  - 2002 Sep
TI  - Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu 
      receptors.
PG  - 317-26
AB  - Previous studies have shown that 5-hydroxytryptamine(2A) (5-HT(2A)) receptor 
      activation induces changes in the pattern of brain-derived neurotrophic factor 
      (BDNF) mRNA expression in the neocortex and hippocampus, and that 5-HT(2A) 
      receptor blockade interferes with the induction of BDNF mRNA by stress. Recent 
      studies have also shown that activation of metabotropic glutamate group II 
      (mGlu2/3) receptors suppresses 5-HT(2A) receptor-stimulated excitatory 
      postsynaptic potentials/currents (EPSP/Cs) in pyramidal neurons in medial 
      prefrontal cortex. Conversely, blockade of mGlu2/3 receptors enhances 
      5-HT-induced EPSCs. The current study examined the effects of the highly 
      selective mGlu2/3 agonist 
      (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate monohydrate 
      (LY354740) and the mGlu2/3 antagonist 
      2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3(xanthy-9-yl)propanoic acid 
      (LY341495) on BDNF mRNA expression in medial prefrontal cortex induced by the 
      hallucinogen and 5-HT(2A/2B/2C) agonist 
      1-(2,5-dimethoxy-4-iodophenethyl)-2-aminopropane (DOI). LY354740 (0.1-10 mg/kg) 
      dose-dependently suppressed DOI-induced BDNF mRNA levels in medial prefrontal 
      cortex. In contrast, the mGlu2/3 antagonist LY341495 (1 mg/kg) enhanced 
      DOI-induced BDNF mRNA levels. BDNF mRNA expression was not altered by 
      administration of the mGlu agonist or the antagonist alone. These results are 
      discussed with respect to a potential role for group II mGlu agonists in the 
      treatment of depression and schizophrenia.
FAU - Gewirtz, Jonathan C
AU  - Gewirtz JC
AD  - Yale School of Medicine, Department of Psychiatry, Ribicoff Research Facilities 
      of the Connecticut Mental Health Center, Room 335d, 34 Park Street, New Haven, CT 
      06508, USA.
FAU - Chen, Andrew C
AU  - Chen AC
FAU - Terwilliger, Rose
AU  - Terwilliger R
FAU - Duman, Ronald C
AU  - Duman RC
FAU - Marek, Gerard J
AU  - Marek GJ
LA  - eng
GR  - K08 MH01551/MH/NIMH NIH HHS/United States
GR  - P01 MH25642/MH/NIMH NIH HHS/United States
GR  - R01 MH45481/MH/NIMH NIH HHS/United States
GR  - R01 MH62186/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Pharmacol Biochem Behav
JT  - Pharmacology, biochemistry, and behavior
JID - 0367050
RN  - 0 (Amino Acids)
RN  - 0 (Amphetamines)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Bridged Bicyclo Compounds)
RN  - 0 (Excitatory Amino Acid Agonists)
RN  - 0 (Excitatory Amino Acid Antagonists)
RN  - 0 (LY 341495)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Metabotropic Glutamate)
RN  - 0 (Xanthenes)
RN  - 0 (metabotropic glutamate receptor 2)
RN  - ONU5A67T2S (eglumetad)
RN  - OOM10GW9UE (4-iodo-2,5-dimethoxyphenylisopropylamine)
SB  - IM
MH  - Amino Acids/pharmacology
MH  - Amphetamines/*pharmacology
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/*biosynthesis
MH  - Bridged Bicyclo Compounds/pharmacology
MH  - Cerebral Cortex/drug effects/*metabolism
MH  - Excitatory Amino Acid Agonists/pharmacology
MH  - Excitatory Amino Acid Antagonists/pharmacology
MH  - In Situ Hybridization
MH  - Male
MH  - Prefrontal Cortex/drug effects/metabolism
MH  - RNA, Messenger/biosynthesis/genetics
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Metabotropic Glutamate/agonists/antagonists & inhibitors/*physiology
MH  - Xanthenes/pharmacology
EDAT- 2002/07/16 10:00
MHDA- 2003/02/06 04:00
CRDT- 2002/07/16 10:00
PHST- 2002/07/16 10:00 [pubmed]
PHST- 2003/02/06 04:00 [medline]
PHST- 2002/07/16 10:00 [entrez]
AID - S0091305702008444 [pii]
AID - 10.1016/s0091-3057(02)00844-4 [doi]
PST - ppublish
SO  - Pharmacol Biochem Behav. 2002 Sep;73(2):317-26. doi: 
      10.1016/s0091-3057(02)00844-4.